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Background: Studies of longitudinal changes in severity and the long-term outcome of
asthma in epidemiological settings are uncommon.
Aim: To assess the outcome of incident asthma in a cohort of subjects who developed
asthma after the age of 20 years.
Methods: This is a prospective study of the outcome of 309 subjects with incident asthma
being included in a case-referent study based on all adults aged 20–60 years living in three
municipalities/towns in Northern Sweden. The subjects fulfilled the criteria for incident
asthma defined as onset of symptoms common in asthma within 12 months prior to the
study and a verified bronchial variability. In 2003, 250 (81%) of the subjects with asthma
were re-examined with structured interview, lung-function test and methacholine test.
Results: At follow-up, 237 (95%) subjects still had an active asthma, i.e. they had
symptoms or used asthma medicines. Among those with active asthma, 65% were using
inhaled cortico-steroids. Severity grading (GINA 2000) showed that 21% had mild
intermittent asthma, 30% mild persistent, 44% moderate persistent, and 5% severe
asthma, contrasting to 75% with moderate or severe asthma at entry. Higher age, higher
BMI and low lung function were associated with greater asthma severity. Twelve subjects
(5%) were in remission. Predictors for remission were non-sensitisation and a normal lung
function. Age, sex, BMI, and smoking habits were not significantly different between those
in remission and those not.Elsevier Ltd. All rights reserved.
udies, Stadsvikens va˚rdcentral, Robertsviksgatan 9, SE-971 89 Lulea˚, Sweden. Tel.: +46 920 28 44 83;
.com (E. Ro¨nmark).
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Outcome of adult onset asthma 2371Conclusions: Remission of adult onset asthma was low. Severity of asthma changed
considerably over time, however, the overall change was towards a milder disease
probably as a result of treatment.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Longitudinal studies of the long-term outcome of asthma
and changes in severity over time are few. In particular
follow-ups of subjects with an adult onset of asthma are
uncommon. Asthma is defined as a chronic disease. How-
ever, remission of asthma may occur, and is more common in
children1,2 than in adults.3,4 The proportion remitting
asthma in a population is dependent upon the age composi-
tion of the samples and the length of follow-up, as relapses
of asthma are common among teenagers5 and young adults6
post a remission period. Furthermore, different definitions
of remission affect the observed remission rates.7
Most studies about the outcome of asthma are based on
cohorts of children or young adults, i.e. studies of asthma
patients diagnosed at young age. Clinical remission of
childhood asthma, i.e. no symptoms and no use of asthma
medicines, has been reported to be around 50%.2,8 Using
these criteria for remission, a 10-year follow-up of a
population study based cohort of adult asthmatics resulted
in a remission of 6%.9 Predictors of remission are not well
known, however, a low level of lung function in childhood,1,4
a high degree of bronchial hyper-reactivity,10 and
being allergic11,12 are reported to be negative factors
for remission. On the contrary, some studies have not
found any association between atopy and remission of
asthma.1,7
Although the severity of asthma varies over time13 and
may be related to long-term outcome, factors related to
degree of severity are not well known and understood. Some
studies have reported that severe asthma among adults is
more common among non-allergic subjects, particularly
among the middle-aged.14 However, change of severity over
time and factors related to change in severity are poorly
studied in population-based studies of asthma.
Within the Obstructive Lung Disease in Northern Sweden
Studies (OLIN) several cohorts are under study. One of them
is a well-characterised cohort of subjects with adult onset
asthma, which has been followed-up. The aim of this study
was to identify factors related to the severity of asthma in
the cohort, change in severity, remission rate of asthma, and
predictors of remission.Materials and methods
Study population
The asthma cohort consisted of cases with incident adult
asthma recruited from 1995 to 1999 in Northern Sweden.
Briefly, the cohort consisted at inception of 309 subjects
aged 20–60 years at time of inclusion. The inclusion criteria
were a history of asthma with onset of symptoms common in
asthma within the last 12 months prior to the inclusion and aphysiologically verified bronchial variability either by a
methacholine test, a reversibility test, or peak expiratory
flow (PEF) variability. The cohort and the inclusion criteria
at baseline have been reported in detail elsewhere.15 Thus,
the examination at inclusion included a structured inter-
view, lung-function test, methacholine test, and further a
skin prick test (SPT). A reversibility test or measures of
morning and evening PEF was performed in subjects with
contra-indication for methacholine testing. The methacho-
line test was not performed in subjects with FEV1o65% of
predicted, in subjects with ischemic or other cardiovascular
disease, or in pregnant women. Subjects with previous
childhood asthma were excluded from the study.
The follow-up visits were performed in 2003, and the
mean follow-up time was 70 months (SD 17). At the follow-
up visit, 250 asthmatics participated at a structured inter-
view, 237 satisfactorily completed a lung-function test,
and 187 a methacholine test. The same methods were
used at the follow-up visits as at the study inclusion.
The ethical committee at the University of Umea˚ approved
the studies.Structured interview
The interview questionnaire included questions from the
OLIN questionnaire,16 the International Union Against
Tuberculosis and Lung Diseases (IUATLD) questionnaire,17
and the interview questionnaire developed for the European
Community Respiratory Health Survey (ECRHS).18
Thus, questions about a family history of asthma and allergy,
rhinitis, hay fever, eczema, smoking habits and occupation
were included.Skin prick test (SPT)
The tests were performed with allergen in 50% glycerol using
a lancet with a tip of 1mm. The allergens were cat, dog,
horse, birch, timothy, mugwort, Dermatophagaides farinae,
D. pteronyssinus, Cladosporium and Alternaria (Soluprick,
ALK, Denmark). A positive reaction was recorded if the
diameter of the wheal was X3mm after 15min.Lung-function test and methacholine test
The lung-function tests were performed following the
American Thoracic Society (ATS) recommendations19 using
a dry spirometer, Mijnhardt Vicatest 5. Swedish reference
values were used.20 Methacholine tests were performed
with an Aiolos nebulizer and an electricity-driven compres-
sor. The method was calibrated against the method
described by Hargreave and Juniper.21
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Remission of asthma: Four different criteria for remission
were defined. First, subjects were defined as having
remitted from their asthma if they did not report any
wheeze or attacks of shortness of breath during the last 12
months, and had not used any asthma medicines during the
last 12 months. Further definitions included also normal lung
function and no hyper-reactivity defined as PC20 at two
different cutoffs of the concentration of methacholine
chloride, X4mg/ml and X8mg/ml, respectively.
Family history of asthma: Asthma among father, mother
or a sibling.
Smoking habits: Smoking habits were classified based on
the reported smoking habits both at baseline and at follow-
up. Subjects were defined as smokers if they smoked every
week or had stopped smoking within the preceding 12
months. Those who had stopped smoking X12 months prior
to the first study were classified as ex-smokers. Five smoking
categories were created: non-smokers, ex-smokers, smo-
kers, quitters, and starters or re-starters.
Rhinitis: Subjects reported that they often had nasal
blocking or a running nose.
Eczema: Subjects reporting past or present eczema.
Body mass index (BMI): Weight in kilograms divided by the
square of the height in meters (kg/m2).
Positive skin test: A weal X3mm to any of the tested
allergens.
Asthma severity: Grading the severity of asthma followed
the GINA classification from year 2000 based on day and
night symptoms, lung function, and medication.22 As the
GINA-classification was developed later than the initial
study design, the frequency of night symptoms was not
surveyed at the inclusion visit of the study. Further, it was
not possible to retrospectively separate moderate and
severe day symptoms, why moderate and severe day
symptoms are grouped together in the inclusion data.Statistical methods
Statistical analyses were performed using SPSS version 11.0.
Comparisons of proportions were tested with chi-square test
or Fishers0 exact test. Continuous data is expressed in mean
7SD, and comparisons of means were tested with two-
tailed Student’s t-test. One way analysis of variance
(ANOVA) was used for test for trends. A p-Value of o0.05
was regarded as statistically significant. Covariates used in
the analyses that may influence both severity and remissionTable 1 Among subjects with incident asthma; number of invi
age and sex.
Age at onset of asthma
20–29 y 30–39 y 40–49 y
Invited, n 89 94 81
Participated, n (%) 52 (58) 84 (89) 72 (88)
Remissiona, n (%) 3 7 2
aRemission defined as no symptoms and no use of asthma medicatof asthma included age, sex, smoking habits, BMI, allergic
sensitisation, concomitant rhinitis, and level of FEV1 in
percent of predicted. Multiple logistic regression models
were performed using these independent variables as risk
factors (odd ratios, OR, with 95% confidence intervals, CI) of
asthma severity. The dependent variable ‘‘asthma severity’’
was dichotomised first by combining the moderate and
severe asthma groups versus the combination of the two
milder groups, and secondly by comparing the severe
asthma group versus the three other severity groups. The
study lacked power to test predictors of remission by using
multivariate analyses.Results
Of the 309 asthmatics included in the original cohort, the
majority were still living in the area and were invited to the
follow-ups, and 250 subjects participated corresponding to
81% of the cohort. The participation rate was lowest, 58%,
among subjects aged 20–29 years, while it was 88–93% in all
other 10-year age groups. The participation rate was lower
among men (Table 1).Remission
Twelve subjects, 4.8%, fulfilled the first criteria for remis-
sion, i.e. did not report any wheeze or attacks of shortness
of breath and had not used any asthma medicines during the
last 12 months. When the criterion of the remission were
strengthened, and also absence of bronchial hyper-reactiv-
ity was included in the criteria, the remission rate
decreased further (Fig. 1). The observation time was similar
in the subjects who had remitted their asthma and those
who had not.
Subjects in remission had a statistically higher mean
FEV1% predicted at the study inclusion compared with
subjects who did not remit their asthma. No major
difference in PC20 at study inclusion was found between
those in remission and those not. None of the 12 subjects in
remission had been a smoker during the study period, while
23% of those with continuing asthma had been a smoker at
either enrolment, follow-up, or at any time during the study
period, p ¼ 0.074. Absence of rhinitis and a negative SPT
were more common among remitters. Age, sex, or BMI did
not differ significantly between those in remission and those
not (Table 2). Ever having had eczema or a family history of
asthma did not influence remission. Neither did use of ICS atted, participants, and subjects in remission at follow-up, by
Sex
50–60 y Men Women All
45 107 202 309
42 (93) 76 (71) 174 (86) 250 (81)
0 2 10 12 (4,8)
ion during the last 12 months.
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remission versus 88% among those still having asthma.
Symptoms and medication in non-remitters
Among the 238 subjects still having asthma at follow-up, 78%
reported wheeze during the last 12 months, 91% attacks of
shortness of breath, and 28% reported night symptoms. Sixty-
five percent of the subjects were using inhaled cortico-
steroids (ICS) as mono-therapy or in combination with long-
acting beta-2-agonists (LABA), and 25% were using fixed
combination of ICS and LABA at follow-up. Further, 49% used
or had used medication for rhinitis or rhino-conjunctivitis.
Severity grading
Grading of severity of asthma using the year 2000 GINA-
classification at follow-up showed that 21% had mild
intermittent asthma, 30% mild persistent, 44% moderate
persistent, and 5% severe asthma. At study inclusion, theTable 2 Basic characteristics in subjects in remission and in su
Variable Still having a
Age at follow-up, mean year (SD) 44.2 (10.4)
Sex, women, (%) 69
BMI at follow-up, mean (SD) 26.8 (4.6)
BMI change from baseline, mean (SD) +0.9 (2.1)
FEV1% predicted at baseline, mean (SD) 92.6 (13.7)
FEV1% predicted at follow-up, mean (SD) 95.2 (15.1)
Positive skin prick test at baseline, (%) 41.8
Rhinitis at baseline, (%) 57.6
Rhinitis at follow-up, (%) 47.5
Smoking any time during study period, (%) 23.1
Smoking categories during the study
Non-smokers n ¼ 108
Ex-smokers n ¼ 75
Quitters n ¼ 19
Smokers n ¼ 29
Starters and re-starters n ¼ 7
0 4
No use of asthma medicines, and
no asthma symptoms
No medicines, no symptoms,
and FEV1>80% of predicted
No medicines, no symptoms,  FEV1>80%
of predicted, and PC20 >8mg/ml
Definition of remission used
No medicines, no symptoms,  FEV1>80% of
predicted, and PC20 >4mg/ml
2 6 
%
Figure 1 Remission of asthma in relation to different criteria
of remission.corresponding figures had been 9%, 16%, while 75% had
either moderate persistent or severe asthma. At enrolment,
the ‘‘severity class driver’’ was symptoms, while at follow-
up use of medicines was the most important driver of
severity class (Table 3). The change of severity class from
baseline to follow-up did not follow any specific pattern,
and the severity grade varied considerably from enrolment
to follow-up (Fig. 2).
At follow-up, severity of asthma (GINA 2000) according to
bi-variate analysis was not significantly related to allergic
sensitisation, although 25% of those with severe asthma had
a positive skin prick test compared to 39% of those with mild
intermittent and 46% with mild persistent asthma. Low FEV1
and increasing age were related to increased asthma
severity (Table 4). Subjects with severe asthma at follow-
up had significantly increased their BMI during the study
period (Table 4). No significant difference in smoking habits
between the severity groups was found, however, nine of
the 12 subjects with severe asthma had never been smokers.
Rhinitis had no influence on the severity of asthma (Table 4).
According to multivariate analyses, only low FEV1 at the
follow-up visit was significantly related to severe asthma:
OR 0.92 (95% CI 0.87–0.97) for a decrease in percent of
predicted with 1% unit. When moderate and severe asthma
were combined, the combination was significantly asso-
ciated with low FEV1 (OR 0.95, 95% CI 0.93–0.97) and
increasing age. Compared with the age group o35 years,
age 455 years yielded an OR of 5.6 (2.0–15.7), age 45–54
years OR 3.1 (1.2–7.9) and age 35–44 years OR 2.7 (1.1–6.8)
for moderate and severe asthma. No other significant
associations were found using the multivariate analyses.Discussion
To the best of our knowledge, this is the first study
investigating the longitudinal outcome of an adult asthma
cohort only including subjects with adult onset asthma with
the strict exclusion of subjects who had asthma duringbjects still having asthma at the follow up visit.
sthma (n ¼ 238) Remission (n ¼ 12) p-Value
40.5 (6.5) 0.219
83 0.356
26.4 (6.1) 0.758
+1.1 (2.2) 0.771
101.3 (12.5) 0.033
101.6 (13.2) 0.214
9.1 0.051
25.0 0.036
8.3 0.007
0 0.074
n ¼ 7
n ¼ 5
n ¼ 0
n ¼ 0
n ¼ 0
ARTICLE IN PRESS
Ta
b
le
3
A
st
hm
a
se
ve
ri
ty
b
as
ed
on
d
ay
sy
m
p
to
m
s,
ni
gh
t
sy
m
p
to
m
s,
lu
ng
fu
nc
ti
on
,
as
th
m
a
m
ed
ic
at
io
n
us
e,
an
d
ov
er
al
l
sc
or
in
g
at
b
as
el
in
e
(t
im
e
fo
r
on
se
t
of
as
th
m
a)
an
d
at
fo
ll
ow
-u
p
ac
co
rd
in
g
to
th
e
G
IN
A
cl
as
si
fi
ca
ti
on
.
Se
ve
ri
ty
D
ay
sy
m
p
to
m
s
N
ig
ht
sy
m
p
to
m
s
Lu
ng
fu
nc
ti
on
A
st
hm
a
m
ed
ic
at
io
n
O
ve
r
al
l
sc
or
in
g
B
as
el
in
e
Fo
ll
ow
-u
p
B
as
el
in
e
Fo
ll
ow
-u
p
B
as
el
in
e
Fo
ll
ow
-u
p
B
as
el
in
e
Fo
ll
ow
-u
p
B
as
el
in
e
Fo
ll
ow
-u
p
M
il
d
in
te
rm
it
te
nt
13
.4
56
.3
a
94
.1
87
.4
86
.3
52
.9
36
.1
9.
2
20
.6
M
il
d
p
er
si
st
en
t
15
.5
23
.9
a
1.
3
40
.3
29
.8
15
.5
30
.3
M
od
er
at
e
p
er
si
st
en
t
71
.0
b
19
.3
a
3.
4
10
.9
11
.9
6.
7
31
.1
73
.5
b
44
.1
Se
ve
re
p
er
si
st
en
t
a
0.
4
a
1.
3
1.
7
1.
8
0
2.
9
a
5.
0
Pe
rc
en
ta
ge
s
b
y
se
ve
ri
ty
(%
)
of
al
l
p
ar
ti
ci
p
an
ts
.
a
no
t
ab
le
to
cl
as
si
fy
.
b
m
od
er
at
e
or
se
ve
re
sy
m
p
to
m
cl
as
s.
E. Ro¨nmark et al.2374childhood. All subjects had their first onset of asthma
symptoms between the ages of 20 to 59 years, and their
asthma and symptoms common in asthma as well had lasted
less than 12 months at the beginning of the observation
period. The study confirms that adult onset asthma is a
chronic disease with a low remission rate. The rate of
clinical remission was 0.8/100/year. The remission rate was
even lower, 0.5/100/year, when absence of bronchial hyper-
reactivity and normal lung function were added to the
criteria defining remission.
The validity of the results must be judged as high due to a
number of reasons. The participation both at enrolment15
and follow-up was high, and the loss of follow-up was low.
The diagnosis of asthma had a high specificity as both a
history of asthma and a physiological verification of the
diagnosis was required, while sensitivity was not optimal.
The enrolled asthmatics had all contacted health care for
their symptoms before the examinations that preceded
inclusion.15 Subjects with mild intermittent asthma may not
have been included and remission may have been somewhat
underestimated. Nevertheless, all enrolled asthmatics had a
clinically relevant disease, which demanded them to seek
health care. Inter-observer bias could be avoided as the
same team examined the patients both at enrolment and at
follow-up.
Previous studies focusing on remission have been based on
asthmatics identified in cross-sectional studies4,9 or in
clinical settings,7,8 and the duration of asthma before the
start of follow-up in these studies has varied considerably. A
well-defined Dutch cohort of asthmatics was followed-up
after 25 years.7 The asthmatics were 13–44 years old at
entry, and in total were 181 subjects followed-up. When
remission was defined as no symptoms, 40% were in
remission and the average remission rate was 1.6/100/year.
Further, 20% were not hyper-reactive, while only about 10%
had a normal lung function, no hyper-reactivity, and were
free from symptoms corresponding to an annual remission
rate of 0.4/100/year,7 a result similar to ours. In Northern
Sweden, an asthma cohort derived from a general popula-
tion sample was identified by using clinically defined criteria
of asthma based on medical history and physiologically
verified bronchial variability. At 10-year follow-up, the
mean annual remission rate was 0.6/100/year.9 Remission
in that study was defined as no symptoms and no use of
asthma medicines during the last 12 months. Remission of
asthma has also been studied within the US Tucson-studies in
a cohort of asthmatics including teenagers at entry. The
remission rate was higher, 22% during 9-year follow-up.4 The
diagnosis of asthma as well as reports about remission in
the Tucson study and some other US studies23,24 were limited
to questionnaire reports without physical examination or
lung function testing. Thus the reported remission rates
were based on reports by the patients and no other
information than absence of symptoms was available.
When the age composition is even younger at study entry,
remission rates are seen to increase. A recently published 12
year follow-up of a Danish sample aged 7–17 years at entry
yielded a remission of 40%.25 In a 30-year follow-up of a
Dutch childhood-asthma cohort, 52% were in clinical
remission, although 57% of those in clinical remission still
were hyper-reactive.8 The greater proportion of those who
were hyper-reactive can in part be explained by results from
ARTICLE IN PRESS
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Figure 2 Change of severity class from inclusion to follow-up.
Table 4 Characteristics of participants by asthma severity at follow-up.
Severity of asthma Difference by
severity, p-Value
Mild
intermittent
Mild
Persistent
Moderate
persistent
Severe
persistent
Female sex, (%) 71.4 66.7 68.6 75.0 0.913
Positive skin prick test, (%) 38.8 45.8 42.3 25.0 0.558
Age, mean year 41.7 43.1 46.5 41.9 0.024
Smoking habits at follow-up, (%)
Non-smokers 44.9 47.2 45.1 75.0 0.465
Ex-smokers 40.8 40.3 38.2 8.3
Smokers 14.3 12.5 16.7 16.7
Rhinitis at follow-up, (%) 53.1 51.4 42.9 41.7 0.549
BMI at follow-upa 26.7 26.2 27.1 28.8 0.252
Change in BMI +0.9 +0.6 +1.0 +2.9 0.007
FEV1% of pred at follow-up,
mean
99.7 100.8 91.2 82.8 o0.001
ICS users 0 77.8 82.9 75.0 o0.001
Ever use of medication for
rhinitis, (%)
44.9 56.3 46.7 63.6 0.402
aBMI was significantly related with moderate and severe asthma versus mild intermittent and mild persistent, p ¼ 0.019.
Outcome of adult onset asthma 2375another Dutch study showing eosinophils, T-cells, mast cells
and interleukin-5 in the mucosa of asthmatics in clinical
remission.26 The somewhat greater proportion in remissionwithout hyper-reactivity in our study compared with the
Dutch studies7,8 may be a result of a rather short follow-up
period of five to six years since the onset of asthma and thus
ARTICLE IN PRESS
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inversely related to remission, the relatively low proportion
of smokers in our study may have contributed to the slightly
higher remission rate compared with the first referred Dutch
study7 and our previous study based on prevalent cases of
asthma.9
As found in the Dutch and the Tucson study,4,7 predictors
of remission in our study were mild disease and normal lung
function at onset of asthma. Active smoking decreased the
possibility of remission, as did rhinitis and allergic sensitisa-
tion. Interestingly, factors for development of asthma in the
same cohort was studied by a case-referent model and risk
factors for incident asthma in adulthood were a family
history of asthma, rhinitis, increased BMI, ex- smoking, and
allergic sensitization.15
An important result was the observation that severity of
asthma changed considerably over time. The GINA guide-
lines from year 2000 suggest four severity grades of
asthma.22 When using the GINA-classification of severity,
three out of four of the asthmatics had moderate or severe
asthma at enrolment mainly due to frequent symptoms, but
less than a half were classified as moderate or severe at
follow-up. At enrolment only 9% had mild intermittent
asthma versus 21% at follow-up. The large proportion
classified as moderate or severe according to GINA at entry
may at least in part be a result related to the new onset of
disease. At onset, the large majority reported frequent
symptoms. Thus most cases of incident asthma did not start
as a mild intermittent or mild persistent asthma. The
incident asthma subjects would not have been adapted to
their airway symptoms, which may explain the frequent
reporting of symptoms.
Our result of changed severity is not supported by results
from the ECRHS, which found severity at baseline to be an
important determinant of severity at follow-up.27 This result
of the ECRHS may be explained by the fact that the
asthmatics in the ECRHS were identified by a cross-sectional
survey in contrast to the asthmatics in our study. The change
of severity observed in our study may reflect the nature and
course of asthma in patients introduced to asthma medica-
tion. A further contributing factor to the observed decline in
overall severity could be the recent onset of asthma, which
may have been accompanied by varying patho-physiological
processes and remodelling of airways parallel to treatment
with ICS in two-thirds of the cohort, delaying processes that
decrease reversibility including remodelling of the air-
ways.28,29 The main reason in the large proportional
decrease in severity is probably an effect of treatment,
mainly maintenance treatment with ICS.22,29
In these asthmatic subjects with an adult onset, some-
what less than a half were sensitised to common airborne
allergens when diagnosed.15 Additionally, the risk factor
pattern was similar both in the atopic and the non-atopic
asthmatics, results conforming to data from the ECRHS.30
Remission was however, inversely associated with allergic
sensitisation, results in accordance with some studies,11,12
but in contrast with other.1,7 Our study shows that in adults,
atopy is a risk factor for the chronicity of asthma. The lower
proportion of sensitised severe asthmatics in our study
conforms to the results from the European study of severe
adult asthma, Enfumosa,14 which showed that the majority
of severe asthmatics had a reduced risk of being sensitisedto common aero-allergens. The results conform also to a
Danish study, in which prognosis with regard to lung function
was poorer in subjects with non-atopic compared with
atopic asthma.31
Multivariate analyses indicated that low lung function at
entry was associated with increased severity. Also increasing
age was significantly associated with severity, and the
association was confirmed by the multivariate analyses.
Increased BMI did not reach statistical significance as a risk
for moderate or severe asthma in the multivariate setting.
However, in subjects with severe asthma at follow-up, BMI
had increased with 2.9 units (mean), which reflects an
average weight increase of about 9 kg, results in accordance
with a French study showing overweight to be related to
uncontrolled asthma.32 Thus, weight reduction could be an
important strategy for improvement in asthma among obese
subjects.33 However, the risk factor pattern for severe
asthma is still poorly understood.
In conclusion, the annual remission rate of newly
identified cases of adult onset asthma followed over five
years was less than 1%. Remission was related to mild
disease, normal lung function at onset, absence of allergic
sensitisation, rhinitis, and being a non-smoker. Atopy was a
predictor of sustained asthma, and increase in BMI was
related to severe asthma at follow-up. Increasing age and
low lung function were predictors of severe asthma. Severity
of asthma according to the GINA-classification varied
considerably though the relatively short follow-up period
and tended to decrease probably as a result of treatment.Conflict of interest statement
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